BioGend Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	231.2	219.02	330.51	163.64	136.32	120.04
Short-Term Investments	300	400	393.76	329.76	552.96	392.99
Cash & Short-Term Investments	531.2	619.02	724.27	493.4	689.28	513.03
Cash Growth	-16.20%	-14.53%	46.79%	-28.42%	34.36%	38.74%
Accounts Receivable	59.38	47.36	26.69	11.27	5.05	0.28
Other Receivables	30.46	33.37	30.67	28.25	23.61	21.62
Receivables	89.84	80.72	57.36	39.52	28.66	21.89
Inventory	19.33	15.96	16.55	4.9	9.03	10.41
Prepaid Expenses	10.29	2	3	4.07	7.57	1.42
Total Current Assets	650.66	717.7	801.18	541.89	734.54	546.75
Property, Plant & Equipment	43.13	49.57	56.2	34.01	8.89	5.94
Long-Term Investments	7.58	8.33	20.34	10	-	69.43
Goodwill	17.09	17.09	17.09	17.09	17.09	-
Other Intangible Assets	83.3	114.07	151.04	210.95	261.92	102.29
Other Long-Term Assets	36.78	5.94	4.64	7.89	1.42	0.94
Total Assets	838.53	912.7	1,050	821.82	1,024	725.34
Accounts Payable	2.69	4.22	2.16	2.08	0.49	1.36
Accrued Expenses	26.88	20.61	16.57	17.22	14.39	14.19
Current Portion of Leases	3.3	3.59	3.65	3.49	3.94	-
Other Current Liabilities	1.85	4.81	23.87	9.07	6.3	2.72
Total Current Liabilities	34.71	33.23	46.25	31.86	25.13	18.27
Long-Term Leases	3.36	5.84	9.44	12.28	0.48	-
Long-Term Unearned Revenue	-	-	2.5	2.5	2.5	2.5
Long-Term Deferred Tax Liabilities	20.83	27.13	35.52	43.92	52.31	-
Total Liabilities	58.9	66.19	93.71	90.56	80.42	20.77
Common Stock	1,244	1,243	1,231	1,031	1,031	920
Additional Paid-In Capital	-	-	-	-	212.85	160.9
Retained Earnings	-461.67	-398.32	-281.85	-325.52	-353.91	-376.33
Comprehensive Income & Other	-20.39	-26.58	-7.96	-2.38	-2.16	-
Total Common Equity	761.51	817.67	940.96	702.86	887.54	704.57
Minority Interest	18.13	28.84	15.81	28.4	55.91	-
Shareholders' Equity	779.63	846.51	956.77	731.27	943.45	704.57
Total Liabilities & Equity	838.53	912.7	1,050	821.82	1,024	725.34
Total Debt	6.65	9.43	13.09	15.77	4.42	-
Net Cash (Debt)	524.55	609.59	711.18	477.64	684.86	513.03
Net Cash Growth	-15.87%	-14.28%	48.90%	-30.26%	33.49%	38.74%
Net Cash Per Share	4.26	4.95	5.91	4.63	6.76	5.87
Filing Date Shares Outstanding	124.36	124.26	123.08	103.08	103.08	92
Total Common Shares Outstanding	124.36	124.26	123.08	103.08	103.08	92
Working Capital	615.94	684.47	754.93	510.03	709.42	528.47
Book Value Per Share	6.12	6.58	7.65	6.82	8.61	7.66
Tangible Book Value	661.12	686.51	772.83	474.82	608.52	602.28
Tangible Book Value Per Share	5.32	5.52	6.28	4.61	5.90	6.55
Machinery	31.86	31.6	31.19	24.66	24.55	23.87
Construction In Progress	-	-	37.57	14.91	-	-
Leasehold Improvements	38.15	38.15	0.34	0.34	0.34	3.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.